Nature Communications (Jun 2022)
The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma
- Josh N. Vo,
- Yi-Mi Wu,
- Jeanmarie Mishler,
- Sarah Hall,
- Rahul Mannan,
- Lisha Wang,
- Yu Ning,
- Jin Zhou,
- Alexander C. Hopkins,
- James C. Estill,
- Wallace K. B. Chan,
- Jennifer Yesil,
- Xuhong Cao,
- Arvind Rao,
- Alexander Tsodikov,
- Moshe Talpaz,
- Craig E. Cole,
- Jing C. Ye,
- Multiple Myeloma Research Consortium,
- P. Leif Bergsagel,
- Daniel Auclair,
- Hearn Jay Cho,
- Dan R. Robinson,
- Arul M. Chinnaiyan
Affiliations
- Josh N. Vo
- Michigan Center for Translational Pathology, University of Michigan
- Yi-Mi Wu
- Michigan Center for Translational Pathology, University of Michigan
- Jeanmarie Mishler
- Michigan Center for Translational Pathology, University of Michigan
- Sarah Hall
- Michigan Center for Translational Pathology, University of Michigan
- Rahul Mannan
- Michigan Center for Translational Pathology, University of Michigan
- Lisha Wang
- Michigan Center for Translational Pathology, University of Michigan
- Yu Ning
- Michigan Center for Translational Pathology, University of Michigan
- Jin Zhou
- Michigan Center for Translational Pathology, University of Michigan
- Alexander C. Hopkins
- Michigan Center for Translational Pathology, University of Michigan
- James C. Estill
- Michigan Center for Translational Pathology, University of Michigan
- Wallace K. B. Chan
- Department of Pharmacology, University of Michigan
- Jennifer Yesil
- Multiple Myeloma Research Foundation
- Xuhong Cao
- Michigan Center for Translational Pathology, University of Michigan
- Arvind Rao
- Department of Computational Medicine and Bioinformatics, University of Michigan
- Alexander Tsodikov
- Department of Biostatistics, School of Public Health, University of Michigan
- Moshe Talpaz
- Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan
- Craig E. Cole
- College of Human Medicine, Breslin Cancer Center, Michigan State University
- Jing C. Ye
- Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan
- Multiple Myeloma Research Consortium
- P. Leif Bergsagel
- Division of Hematology, Department of Internal Medicine, Mayo Clinic
- Daniel Auclair
- Multiple Myeloma Research Foundation
- Hearn Jay Cho
- Multiple Myeloma Research Foundation
- Dan R. Robinson
- Michigan Center for Translational Pathology, University of Michigan
- Arul M. Chinnaiyan
- Michigan Center for Translational Pathology, University of Michigan
- DOI
- https://doi.org/10.1038/s41467-022-31430-0
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 13
Abstract
The genetic factors involved in disease progression and drug resistance in multiple myeloma (MM) are varied and complex. Here, genomic and transcriptomic profiling of 511 relapsed and refractory MM patients reveals genetic alterations in several oncogenic pathways contributing to progression and resistance to MM therapies.
